Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
RPTX 
Repare Therapeutics Inc (RPTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: RPTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 1 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -63.43% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 71.31M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 4 | Beta 0.93 | 52 Weeks Range 0.89 - 4.07 | Updated Date 08/29/2025 |
52 Weeks Range 0.89 - 4.07 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.58 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-08 | When - | Estimate -0.56 | Actual -0.39 |
Profitability
Profit Margin - | Operating Margin (TTM) -8024.8% |
Management Effectiveness
Return on Assets (TTM) -38.82% | Return on Equity (TTM) -69.96% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -37940367 | Price to Sales(TTM) 285.25 |
Enterprise Value -37940367 | Price to Sales(TTM) 285.25 | ||
Enterprise Value to Revenue 0.02 | Enterprise Value to EBITDA 0.58 | Shares Outstanding 42959200 | Shares Floating 22715092 |
Shares Outstanding 42959200 | Shares Floating 22715092 | ||
Percent Insiders 1.25 | Percent Institutions 64.94 |
Upturn AI SWOT
Repare Therapeutics Inc
Company Overview
History and Background
Repare Therapeutics Inc. was founded in 2016. It is a clinical-stage precision oncology company focused on discovering, developing and commercializing novel therapeutics targeting specific vulnerabilities of tumors in genetically defined patient populations.
Core Business Areas
- Oncology Therapeutics: Focuses on developing precision oncology therapies targeting specific cancer vulnerabilities.
- Discovery Platform: Utilizes its proprietary SNIPRx platform to identify and develop new drug candidates.
Leadership and Structure
Repare Therapeutics is led by a management team with expertise in drug discovery, development, and commercialization. The organizational structure includes research and development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- Camonsertib: An oral, selective and potent ATR (ataxia telangiectasia and Rad3-related protein kinase) inhibitor. The product is being developed for cancers with ATR pathway vulnerabilities. Competitors include Vertex Pharmaceuticals and other companies developing ATR inhibitors.
- RP-6306: A PKMYT1 inhibitor being developed for the treatment of solid tumors with CCNE1 amplification or FBXW7 mutations. Competitors include other companies developing PKMYT1 inhibitors.
Market Dynamics
Industry Overview
The oncology therapeutics market is large and growing, driven by increasing cancer incidence and advances in cancer treatment. Precision oncology, which targets specific genetic or molecular characteristics of tumors, is a rapidly evolving area.
Positioning
Repare Therapeutics is positioned as a precision oncology company with a focus on developing novel therapies targeting specific vulnerabilities in cancer cells. Its SNIPRx platform provides a competitive advantage in identifying and developing new drug candidates.
Total Addressable Market (TAM)
The total addressable market for precision oncology is estimated to be in the billions of dollars. Repare Therapeutics is focused on specific subsets of cancer patients, providing a defined market opportunity.
Upturn SWOT Analysis
Strengths
- Proprietary SNIPRx platform
- Experienced management team
- Strong intellectual property position
- Clinical-stage pipeline
Weaknesses
- Limited revenue to date
- Dependence on clinical trial success
- Competition from larger pharmaceutical companies
- High cash burn rate
Opportunities
- Expansion of pipeline through SNIPRx platform
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Regulatory approvals for lead programs
Threats
- Clinical trial failures
- Competition from other companies
- Regulatory hurdles
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- VXRT
- BMY
- AZN
Competitive Landscape
Repare Therapeutics competes with both large pharmaceutical companies and other smaller biotech companies in the precision oncology space. Its competitive advantage lies in its SNIPRx platform and focus on specific cancer vulnerabilities.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in the company's pipeline advancement and fundraising activities.
Future Projections: Future growth depends on the success of its clinical programs and partnerships. Analyst estimates vary, but generally project revenue growth upon successful commercialization of its drug candidates.
Recent Initiatives: Recent initiatives include advancing its lead programs through clinical trials and expanding its pipeline through its SNIPRx platform.
Summary
Repare Therapeutics is a clinical-stage precision oncology company with a promising SNIPRx platform. Success depends on clinical trials and partnerships. There is competition and regulatory risks to consider. The company is currently burning cash and is yet to commercialize a drug, indicating there is high risk, but good potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Repare Therapeutics Inc. SEC filings (e.g., 10-K, 10-Q)
- Repare Therapeutics Inc. website
- Analyst reports
- Market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary. Financial data is based on publicly available information and may not be complete or accurate. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Repare Therapeutics Inc
Exchange NASDAQ | Headquaters Montreal, QC, Canada | ||
IPO Launch date 2020-06-19 | President, CFO, CEO & Director Mr. Steve Forte CPA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 129 | Website https://www.reparerx.com |
Full time employees 129 | Website https://www.reparerx.com | ||
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 clinical trial for the treatment of solid tumors; and lunresertib (RP-6306), a selective and potent oral small molecule inhibitor of Protein Kinase Membrane-associated tyrosine-and threonine-specific cdc-2 inhibitory kinase that is in Phase 1/2 clinical trial. In addition, the company is developing RP-1664, an oral PLK4 inhibitor in Phase 1 clinical trial to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, an inhibitor of adenosinetriphosphatase activity on the helicase domain of DNA polymerase theta that is in Phase 1 clinical trial. The company has strategic collaborations with Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.